New IGF-TRAP as cancer treatment
- Recombinant protein
- Hematological tumors
- IGF signaling pathway
Insulin Growth Factor (IGF) is a major target in oncology for solid and hematologic tumors. Unfortunately, up to now, the different strategies elaborated to encounter this pathway failed to demonstrate a significant efficacy. This can be explained by the complexity of the IGF signaling pathway that involves multiple receptors and ligands.
A new IGFBP3 recombinant protein antagonizing the IGF signaling pathway was designed to simultaneously neutralizing IGF-I & II to prevent their interaction with their different receptors. They have also developed a companion diagnostic enabling to identify patient who will respond to the treatment.
The anti-tumor efficacy of the recombinant IGFBP3 was established in vivo (multiple myeloma, colorectal carcinoma, Ewing sarcoma, adrenocortiacl carcinoma...). Lutech is funding a program to validate the production of the protein in a pre-industrial system using CHO cells as well as pharmacokinetics studies and complementary efficacy characterization.
- Treatment of solid tumors and hematological malignancies
- Combination therapy
- Application in ophtalmology and growth disorders
- Simultaneous neutralization of both ligands IGF-I and IGF-II
- No interaction with the insulin pathway (no adverse metabolic effects)
- Resistance to proteolysis
- Companion diagnostic developed
- Patent application filed in 2012 and granted in the US, Europe, Canada and Japan
Health | Number ref.: #MA00283
Ooncology, Treatment, Recombinant protein, Hematological tumors, IGF signaling pathway, Antagonist